Search Options Stock News and Analysis

Signal Says Biotech Stock Isn't Done Climbing Yet

https://www.schaeffersresearch.com/content/analysis/2020/10/20/signal-says-biotech-stock-isnt-done-climbing-yet

10/20/2020 1:38 PM

The shares of Halozyme Therapeutics, Inc (NASDAQ:HALO) are up 3.6% to trade at $30.54 at last check, after earlier hitting an all-time-high of $30.88. And while the biotech company already enjoys an i...

Tech, Drug Stocks Lift Wall Street Spirits

https://www.schaeffersresearch.com/content/news/2020/07/10/tech-drug-stocks-lift-wall-street-spirits

7/10/2020 1:26 PM

Highlighting the second week of July was a multi-day surge out of the Nasdaq Composite (IXIC) to record highs, thanks to an outperforming tech sector. FAANG stocks soared for a majority of the week, a...

Drug Stock May Be Overdue for a Short Squeeze

https://www.schaeffersresearch.com/content/options/2020/07/09/drug-stock-may-be-overdue-for-a-short-squeeze

7/9/2020 2:46 PM

The shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) are down 1.4% to trade at $28.12 at last check. However, just three days ago the security hit an all-time-high of $29.34, and the stock now s...

Long-Term Signal Says Buy This Biotech

https://www.schaeffersresearch.com/content/analysis/2019/11/07/long-term-signal-says-buy-this-biotech

11/7/2019 12:56 PM

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is trading 1.2% lower today at $16.70, taking a breather after a 10.5% gap higher on Tuesday following corporate restructuring news. Despite today's pullback,...

Halozyme Therapeutics Stock Gutted By Revenue Miss, Downgrade

https://www.schaeffersresearch.com/content/news/2018/05/11/halozyme-therapeutics-stock-gutted-by-revenue-miss-downgrade

5/11/2018 10:03 AM

Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is down 9.3% to trade at $18.12 this morning, after the biotech company reported first-quarter revenue short of analysts' forecasts, as well as a weaker...

PEOPLE ALSO SEARCH FOR